Graybug Vision Inc (GRAY): Price and Financial Metrics
GRAY Price/Volume Stats
| Current price | $5.50 | 52-week high | $22.12 |
| Prev. close | $6.17 | 52-week low | $5.00 |
| Day low | $5.00 | Volume | 24,600 |
| Day high | $6.08 | Avg. volume | 2,165 |
| 50-day MA | $8.79 | Dividend yield | N/A |
| 200-day MA | $11.66 | Market Cap | 8.64M |
GRAY Stock Price Chart Interactive Chart >
Graybug Vision Inc (GRAY) Company Bio
GrayBug is a pharmaceutical company that focuses on developing the next generation of products for the treatment of chronic vision-threatening diseases of the retina and optic nerve. The company is currently developing a continuum of proprietary micro – and nanoparticle controlled release technologies and implants for strategic partnership and its own therapeutic products for major ocular disease indications including wet AMD and Glaucoma. The company was founded in 2011 and headquartered in Baltimore, Maryland.
Latest GRAY News From Around the Web
Below are the latest news stories about GRAYBUG VISION INC that investors may wish to consider to help them evaluate GRAY as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday morning! |
Graybug Vision Agrees To Merge With Inflammatory Disease-Focused BiopharmaGraybug Vision Inc (NASDAQ: GRAY) and CalciMedica Inc (CalciMedica) have announced a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will further develop CalciMedica's lead product candidate Auxora for inflammatory diseases, such as acute pancreatitis, asparaginase-associated pancreatitis, acute kidney injury, and acute hypoxemic respiratory failure. Auxora, which modulates the immune response and protects against tissue cell injury, has bee |
Graybug and CalciMedica Enter into Definitive Merger Agreement– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024 – Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023 – Companies will host joi |
Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and nine months ended September 30, 2022. Financial Results for the Three Months Ended September 30, 2022 Net loss for the quarter ended September 30, 2022 was $9.8 million compared to $8.0 million for the s |
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate DevelopmentsBALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the three and six months ended June 30, 2022. Recent Corporate Developments Announced review of strategic alternatives — On June 28, 2022, Graybug announced that its Board of Directors w |
GRAY Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -91.98% |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -72.68% |
| 2021 | -93.69% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...